Earnings call transcript: Tarsus Pharmaceuticals Q1 2026 beats EPS forecast, stock dips

Tarsus Pharmaceuticals reported better-than-expected Q1 2026 earnings, with an EPS of -$0.16 against a forecast of -$0.30 and revenue of $162 million, surpassing the $153.12 million projection. Despite this strong financial performance, including an 85% year-over-year growth in XDEMVY sales, the stock experienced a slight dip of 0.43% in aftermarket trading. The company reaffirmed its full-year 2026 guidance, driven by increasing physician adoption, a successful DTC campaign, and an expanding pipeline including Lyme disease prevention and ocular rosacea programs, with expected top-line data in H1 2027 for both.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned